Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?

Breast Cancer Research and Treatment

Volumn 60, Issue 1, 2000, Pages 1-8

  Rosenberg Zand, Rachel S ^a,b   Grass, Linda ^b   Magklara, Angeliki ^b,c   Jenkins, David J A ^a   Diamandis, Eleftherios P ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiestrogens; Antiprogestins; Estrogens; Progestins

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; LUCIFERASE; MIFEPRISTONE; NORGESTREL; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN PS2; TISSUE KALLIKREIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; GENE CONSTRUCT; GENETIC TRANSFECTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; REPORTER GENE;

BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIFEPRISTONE; PROGESTINS; PROSTATE-SPECIFIC ANTIGEN; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE KALLIKREINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034066845     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006334132303     Document Type: Article

References (25)

1. 1. Howell A, DeFriend D, Robertson J, Blamey R, Walton P: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30, 1995
2. 2. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991
3. 3. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG: Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87: 6883-6887, 1990
4. 4. Gibson MK, Nemmers LA, Beckman WC, Jr, Davis VL, Curtis SW, Korach KS: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2010, 1991
5. 5. Dauvois S, White R, Parker MG: The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106: 1377-1388, 1993
6. 6. Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A: 576-588, 1996
7. 7. Kangas L, Nieminen AL, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R: A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109-113, 1986
8. 8. Favoni RE, de Cupis A: Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Trends in Pharmaceutical Sciences 19: 406-415, 1998
9. 9. Loser R, Seibel K, Roos W, Eppenberger U: In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen: Eur J Cancer Clin Oncol 21: 985-990, 1985
10. 10. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32: 1031-1036, 1983
11. 11. Toko T, Sugimoto Y, Matsuo K, Yamasaki R, Takeda S, Wierzba K, Asao T, Yamada Y: TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. Eur J Cancer 26: 397-404, 1990
12. 12. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC: Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851-5858, 1991
13. 13. Kraus WL, Weis KE, Katzenellenbogen BS: Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist-and antagonist-occupied progestin receptors. Mol Cell Biol 15: 1847-1857, 1995
14. 14. Jeng MH, Langan-Fahey SM, Jordan VC: Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 132: 2622-2630, 1993
15. 15. Nawaz Z, Stancel GM, Hyder SM: The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 59: 372-376, 1999
16. 16. Catherine WH, Jordan VC: Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92: 39-47, 1995
17. 17. Hall RE, Tilley WD, McPhaul MJ, Sutherland RL: Regulation of androgen receptor gene expression by steroids and retinoic acid in human breast-cancer cells. Int J Cancer 52: 778-784, 1992
18. 18. Christopoulos TK, Diamandis EP: Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 64: 342-346, 1992
19. 19. Yu H, Diamandis EP, Zarghami N, Grass L: Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 32: 291-300, 1994
20. 20. Black MH, Magklara A, Obiezu CV, Melegos DN, Diamandis EP: Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross reactivity from prostate specific antigen. Clin Chem 45: 790-799, 1999
21. 21. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL: Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 41: 399-410, 1990
22. 22. Horowitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167-1177, 1996
23. 23. Lange CA, Richer JK, Shen T, Horowitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogenactivated protein kinase pathways. J Biol Chem 273: 31308-31316, 1998
24. 24. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horowitz KB: Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273: 31317-31326, 1998
25. 25. Weaver CA, Springer PA, Katzenellenbogen BS: Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyl transferase fusion genes transfected into MCF-7 human breast cancer cells. Mol Endocrinol 2: 936-945, 1988